Table 1.

Demographic Characteristics, HCV Medical Characteristics, and Comorbid Disease Status of MMT and non-MMT Patients with Chronic HCV Infection

	MMT Group (N=80)	Non-MMT group (N=80)
Age (mean yrs ±SD)	43 (±10)	44 (±10)
Male	61%	61%
Race
Caucasian	80%	80%
African-American	14%	14%
Native American or Hawaiian/Pacific Islander	3%	6%
Mixed	3%	0%
Ethnicity
Hispanic	21%	16%
Medicaid*	70%	51%
Current PCP**	80%	94%
Reported Lifetime IV Drug Use***	88%	51%
Genotype 1	81%	77% (55/71†)
Viral Load > 2 million IU/ml	38%	45% (32/71†)
Viral Load - median (IU/ml)	1.2 million	1.3 million
Liver Biopsy – median grade (Knodell)	2 (n = 17)	2 (n = 45)
Liver Biopsy – median stage (Knodell)	2 (n = 17)	2 (n = 47)
Serum ALT - IU/ml (n, % > ULN°)**	40/79† (51%)	54/76† (71%)
Serum AST - IU/ml (n, % > ULN°)	46/79† (58%)	56/76† (74%)
Serum GGT - IU/ml (n, % > ULN°)	44/74† (59%)	23/38† (61%)
Co-infection with HIV	4/80 (5%)	2/80 (3%)
Any comorbid chronic medical diagnosis	73/80 (91%)	68/80 (85%)
Number of comorbid medical diagnoses (mean)	3	3
Lifetime diagnosis of one or more SUDs	80/80 (100%)	64/80 (80%)

^*p ≤ 0.05

^**p ≤ 0.01

^***p ≤ 0.001

PCP = Primary Care Provider

^°Upper limit of normal

^†Some patients in each group did not have available data for this variable, leading to an N < 80

ALT = alanine aminotransferase

SUDs= substance use disorders

AST= aspartate aminotransferase

HIV = Human Immunodeficiency Syndrome